Table 1. Demographic and preoperative characteristics.
| Sample (n=66) n (%) | |||
|---|---|---|---|
| Gender | 48 (72.7) | ||
| Male | 18 (27.3) | ||
| Female | 59.3 (±8.03) | ||
| Mean age, years (SD) | 23 (34.8) | ||
| Comorbidities | 12 (18.1) | ||
| SAH | 3 (4.5) | ||
| Diabetes | 1 (1.5) | ||
| Cardiopathy | 37 (56) | ||
| Pneumopathy | 36 (54.5) | ||
| Smoking | 5 (7.57) | ||
| Alcoholism | 58 (87.8) | ||
| ASA Score | 1 (1.5) | ||
| I II III | 2 (3) | ||
| EGD | |||
| Local of lesion | |||
| 20 cm DA | 2 (3) | ||
| 20 – 30 cm DA | 33 (50) | ||
| 30 – 40 cm DA | 17 (25.7) | ||
| Distal esophagus | 6 (9) | ||
| EGT Siewert I | 4 (6) | ||
| EGT Siewert II | 1 (1.5) | ||
| Histological type | |||
| Adenocarcinoma | 8 (12.2) | ||
| Squamous cell | 54 (81.8) | ||
| Carcinoma | 1 (1.5) | ||
| High-grade dysplasia | 1 (1.5) | ||
| Not informed | 2 (3) | ||
| Histologic grade | |||
| Grade 1 | 4 (6.1) | ||
| Grade 2 | 22 (33.3) | ||
| Grade 3 | 2 (3) | ||
| Undifferentiated | 3 (4.5) | ||
| Undetermined | 35 (53) | ||
| Clinical staging (TNM) | |||
| Tumor | |||
| T1 | 4 (6.1) | ||
| T2 | 23 (34.8) | ||
| T3 | 28 (42.4) | ||
| T4 | 5 (7.6) | ||
| TX | 6 (9.1) | ||
| Nodes | |||
| N0 | 40 (60.6) | ||
| N1 | 16 (24.2) | ||
| N2 | 1 (1.5) | ||
| NX | 9 (13.6) | ||
| Metastasis | |||
| M0 | 57 (86.4) | ||
| MX | 9 (13.6) | ||
| Neoadjuvant therapy | |||
| Chemotherapy | 2 (3) | ||
| Radiotherapy | 2 (3) | ||
| Radiotherapy + Chemotherapy | 32 (48.5) | ||
| None | 30 (45.5) | ||
| Neoadjuvant therapy complete | |||
| Response | 16 (44) | ||
SD: standard deviation; SAH: systemic arterial hypertension; ASA: American Society of Anaesthesiologists; EGD: Esophagogastroduodenoscopy; DA: dental arch; EGT: esophagogastric transition.